Liver Biomarkers Explained: ALT, AST, GGT, and What They Indicate in Fatty Liver

Why liver enzymes matter in assessing fatty liver

When a doctor orders blood work for a patient with suspected fatty liver disease, the first numbers they look at are usually the liver enzymes ALT, AST, and GGT. These enzymes are not disease‑specific, but they give a snapshot of how the liver cells are coping with stress, injury, or inflammation. Understanding what each test measures, how the values are interpreted, and what they tell us about fatty liver helps patients and clinicians make informed decisions about lifestyle changes, medication, and follow‑up monitoring.

What ALT, AST, and GGT actually are

Alanine aminotransferase (ALT)

ALT is an enzyme found primarily in the cytoplasm of hepatocytes (the main functional cells of the liver). It catalyzes the transfer of an amino group from alanine to α‑ketoglutarate, producing pyruvate and glutamate. Because ALT resides mainly in liver cells, a rise in its serum concentration usually reflects direct hepatocellular injury.

Aspartate aminotransferase (AST)

AST is also a transaminase, but it is less liver‑specific. It is present in mitochondria and cytoplasm of hepatocytes, but it is abundant in heart muscle, skeletal muscle, kidney, brain, and red blood cells. Elevated AST can therefore arise from non‑hepatic sources such as vigorous exercise, muscle trauma, or cardiac injury.

Gamma‑glutamyl transferase (GGT)

GGT is a membrane‑bound enzyme involved in glutathione metabolism and the transfer of gamma‑glutamyl groups. It is located on the biliary epithelium and on hepatocyte membranes facing the bile canaliculi. Serum GGT rises when the biliary tract is stressed or when liver cells are exposed to oxidative stress, alcohol, or certain drugs.

Normal reference ranges and factors that shift them

Reference ranges differ slightly between laboratories, but typical adult values are:

• ALT: 7–56 U/L
• AST: 10–40 U/L
• GGT: 9–48 U/L (men) and 8–35 U/L (women)

Several factors can move these limits:

• Age – older adults often have slightly higher baseline ALT and AST.
• Sex – men usually have higher GGT and AST levels.
• Body mass index (BMI) – obesity can raise ALT modestly even without overt liver disease.
• Medications – statins, anti‑epileptics, and some antibiotics may elevate ALT or GGT.
• Alcohol intake – regular consumption can increase GGT and, at higher doses, ALT/AST.
• Physical activity – intense exercise may transiently raise AST.

How each enzyme relates to fatty liver disease

Fatty liver, or hepatic steatosis, occurs when more than 5 % of liver cells accumulate triglycerides. The condition exists on a spectrum:

1. Simple steatosis – fat accumulation without inflammation.
2. Non‑alcoholic fatty liver disease (NAFLD) – includes simple steatosis plus metabolic risk factors.
3. Non‑alcoholic steatohepatitis (NASH) – steatosis with inflammatory injury and fibrosis.

Enzyme patterns help differentiate these stages.

ALT in fatty liver

ALT is the most sensitive marker for hepatocellular injury in NAFLD. In simple steatosis, ALT may be normal or mildly elevated (often < 2 × the upper limit of normal, ULN). In NASH, ALT frequently exceeds 2 × ULN and can rise up to 5 × ULN. However, ALT alone cannot confirm NASH; a biopsy is required for definitive diagnosis.

AST and the AST/ALT ratio

Because AST is also released from muscle, its absolute value is less specific. Clinicians often look at the AST/ALT ratio:

• Ratio < 1 – typical of early NAFLD or NASH.
• Ratio ≈ 1 – may indicate progressing disease.
• Ratio > 2 – suggests advanced fibrosis or cirrhosis, especially when ALT has fallen while AST remains elevated.

A rising ratio, even if both enzymes are modest, flags the need for more detailed evaluation.

GGT as a marker of oxidative stress and bile‑related injury

GGT rises when the liver is exposed to chronic oxidative stress, a hallmark of NASH. Elevated GGT is also strongly associated with alcohol use and metabolic syndrome. In fatty liver patients, a high GGT (especially > 2 × ULN) often correlates with higher body weight, insulin resistance, and a greater likelihood of fibrosis on imaging.

Interpreting a typical fatty‑liver lab panel

Consider a 48‑year‑old patient with BMI = 32 kg/m², fasting glucose = 112 mg/dL, and the following labs:

The pattern – ALT > AST, high GGT, and normal platelets – fits a typical NASH profile in an overweight adult. The next steps usually involve liver imaging (ultrasound or FibroScan) and possibly a risk‑stratification score such as the NAFLD Fibrosis Score.

When enzymes are normal but fatty liver is present

Up to 30 % of patients with imaging‑confirmed steatosis have normal ALT, AST, and GGT. Normal enzymes do not guarantee a benign disease course. Reasons include:

• Early disease stage where injury has not yet caused enzyme leakage.
• Genetic variations affecting enzyme release.
• Individual differences in hepatic clearance of enzymes.

In such cases, clinicians rely more heavily on imaging findings, metabolic risk assessment, and non‑invasive fibrosis scores.

Other biomarkers that complement ALT, AST, and GGT

While ALT, AST, and GGT are the cornerstone tests, additional markers improve diagnostic accuracy:

• Serum ferritin – elevated in many NASH patients; reflects iron overload and inflammation.
• High‑sensitivity C‑reactive protein (hs‑CRP) – a systemic inflammation marker that rises with metabolic syndrome.
• Cytokeratin‑18 fragments (M30/M65) – apoptosis markers studied for NASH detection, though not widely used in routine practice.
• Fibrosis‑specific scores – NAFLD Fibrosis Score, FIB‑4, and APRI combine age, enzyme levels, platelet count, and albumin to estimate fibrosis risk.

How lifestyle and treatment affect enzyme levels

Improving insulin sensitivity, reducing weight, and limiting alcohol intake can lower ALT, AST, and GGT within weeks to months.

Weight loss

Losing 5–10 % of body weight often reduces ALT by 30–50 % and can normalize GGT. The effect is dose‑dependent: larger weight reductions produce greater enzyme declines.

Exercise

Aerobic activity of moderate intensity (150 min/week) improves insulin resistance and may lower ALT even without weight loss. Resistance training adds benefit by preserving lean muscle mass, which helps keep AST levels stable.

Alcohol moderation

Reducing alcohol to < 20 g/day (women) or < 30 g/day (men) typically drops GGT within 2–4 weeks. Persistent elevation after abstinence suggests an underlying hepatic process beyond alcohol.

Medications

Pioglitazone and vitamin E have been studied for NASH; both can modestly lower ALT and improve histology. However, medication decisions depend on individual risk profiles and should be guided by a hepatologist.

When to refer for further evaluation

Enzyme patterns alone do not dictate management, but certain thresholds prompt specialist referral:

• ALT or AST > 3 × ULN, especially if persistent over 3 months.
• AST/ALT ratio > 1 with declining platelet count.
• GGT > 2 × ULN combined with metabolic risk factors.
• Any enzyme elevation in conjunction with unexplained jaundice, ascites, or encephalopathy.

Referral facilitates liver imaging (ultrasound, MRI‑PDFF, or FibroScan) and possibly a liver biopsy to confirm NASH or assess fibrosis stage.

Key take‑aways for patients

• ALT, AST, and GGT are useful clues but not definitive diagnoses.
• Elevated ALT usually means liver cells are leaking enzymes; a higher ALT than AST is typical early in fatty liver disease.
• A rising AST/ALT ratio may signal advancing fibrosis.
• High GGT often accompanies oxidative stress, alcohol use, and metabolic syndrome.
• Normal enzymes do not rule out disease; imaging and risk scores remain essential.
• Lifestyle changes have measurable, often rapid, effects on enzyme levels.
• Persistent or markedly high values warrant specialist assessment.